TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02223065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Study: NCT02460081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDA-002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDA-002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01643746

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supera Stent
Description: Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Life Stent
Description: Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
Study: NCT01193543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calanus oil
Description: 1 gram twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: 1 gram twice daily
Study: NCT03702101

Intervention type: DEVICE
Intervention: Auricular point detector
Description: This device is only for auricular detection. No additional intervention will be delivered.
Study: NCT00555126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warming with endovascular catheter + forced air warming
Description: Warming after Randomization
Study: NCT00696202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena (BAY86-5028)
Description: Intrauterine levonorgestrel containing device (market product)
Study: NCT03568032

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of intima media thickness of carotid artery
Description: IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of intima media thickness of carotid artery
Description: IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection and measurement of carotid plaques
Description: Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection and measurement of carotid plaques
Description: Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid Color Flow Duplex Testing
Description: Velocity measurement of carotid artery to determine carotid stenosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid Color Flow Duplex Testing
Description: Velocity measurement of carotid artery to determine carotid stenosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: Cognitive assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: Cognitive assessment

Intervention type: OTHER
Intervention: Medical history of cardiovascular risk factors and cardiovascular diseases
Description: Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.

Intervention type: OTHER
Intervention: Medical history of cardiovascular risk factors and cardiovascular diseases
Description: Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
Study: NCT03534115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAC
Description: solution containing NAC

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04056000

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200 mg of caffeine, 60 minutes before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200 mg of caffeine, 60 minutes before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-carbohdyrate breakfast
Description: Ingestion of a high-carbohydrate breakfast 60 minutes before exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-minutes of steady state exercise
Description: See intervention name

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-minutes of steady state exercise
Description: See intervention name

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-minutes of steady state exercise
Description: See intervention name
Study: NCT01021488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg/d for 14days
Description: Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin only
Description: enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
Study: NCT03084068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human dehydrated umbilical cord allograft
Description: human dehydrated umbilical cord allograft

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Open rotator cuff surgery with standard suture repair
Study: NCT03905356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.
Study: NCT02035397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Study: NCT03406000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (U300)
Description: Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection
Study: NCT00001941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daclizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daclizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daclizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daclizumab
Study: NCT00297778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Dopamine agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00591604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
Study: NCT04612478

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Directed Exercise Program
Description: The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinic-Based Physical
Description: Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
Study: NCT02539238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal practice and real-time feedback
Description: Brief CPR practice distributed during working hours with real-time feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longitudinal practice and real-time feedback
Description: Brief CPR practice distributed during working hours with real-time feedback
Study: NCT02044614

Intervention type: OTHER
Group type: OTHER
Intervention: Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis
Study: NCT03719378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre Operative Oral Fluids
Description: Patients will be self hydrating prior to their total knee replacement.
Study: NCT02679547

Intervention type: OTHER
Intervention: Breastfeeding
Description: All of the participants and patients will have a questionnaire about their breastfeeding

Intervention type: OTHER
Intervention: Breastfeeding
Description: All of the participants and patients will have a questionnaire about their breastfeeding
Study: NCT04112641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
Study: NCT03144778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT02157129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipoAerosol© inhalation
Description: LipoAerosol© inhalation, 5x/d for 30min
Study: NCT04240860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platlet rich plasma
Description: Drug: PRP PRP subendometrial infusion~Device: ovum oickup needle PRP subendometrial infusion by hysteroscopic guided ovum pickup needle day 9 of the cycle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial scratch
Description: Three Snip Hysteroscopic Endometrial Scratching in luteal phase of preceeding cycle
Study: NCT01625208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined nerve block
Description: Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular block
Description: Standard supraclavicular brachial plexus block
Study: NCT03515629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810/ipi
Description: REGN2810 plus ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810/chemo/ipi
Description: REGN2810 plus chemotherapy plus Ipilimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Reference drug administered IV infusion
Study: NCT03161626

Intervention type: DRUG
Intervention: Coagadex
Description: Plasma-driven blood coagulation factor X concentration
Study: NCT01433744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
Study: NCT04205149

Intervention type: OTHER
Intervention: ERAS post-operative pathway
Description: ERAS Pathway
Study: NCT04217005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensory Feedback
Description: Subjects will receive a sensory feedback provided by electrical stimulation
Study: NCT04615156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-2-fluoro-2-deoxy-D-glucose
Description: Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
Study: NCT02629549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: Infusion of OTL38 prior to surgery
Study: NCT02359890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® SMARTTOUCH® (RF ablation treatment)
Description: Radiofrequency Ablation Treatment
Study: NCT04127409

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Chicken-meat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Chicken-meat

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Eggs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Eggs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3-PUFA Enriched Chicken-meat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3-PUFA Enriched Chicken-meat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3PUFA Enriched Eggs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3PUFA Enriched Eggs
Study: NCT04645095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack
Description: All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack
Description: All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack
Description: All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
Study: NCT03849781

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeoBeat with a visible display
Description: NeoBeat (Laerdal Medical) is a CE approved novel heart rate meter, able to detect heart rate in newborns within seconds of birth. The NeoBeat uses ECG dry-electrodes in a snug-fit abdomen-shaped buckle for rapid application around the newborn's abdomen or thorax. It allows healthcare providers to reliably assess heart rate of the newborn immediately after birth and continuously during resuscitation.
Study: NCT01066052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hGH
Description: Subcutaneous administration.
Study: NCT02235233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium Tc 99M Mebrofenin
Description: Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99M Mebrofenin
Description: Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
Study: NCT03841383

Intervention type: DIAGNOSTIC_TEST
Intervention: Echo stress dipyridamole
Description: Echo stress dipyridamole

Intervention type: DIAGNOSTIC_TEST
Intervention: Echo stress dipyridamole
Description: Echo stress dipyridamole
Study: NCT01323881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation
Description: Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
Study: NCT03197402

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched protein gel delivery system
Description: Leucine enriched

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein gel delivery system
Description: Non-leucine enriched
Study: NCT00977002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Pressure Noninvasive ventilation
Description: Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalatory O2
Description: Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
Study: NCT00619385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
Study: NCT02512913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted/enhanced MAPS
Description: The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
Study: NCT03788499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage of Maxillofacial and Oral Cavity
Description: Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
Study: NCT00334490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 12.5 mg Sildenafil once with optional second dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 12.5 mg orally once with optional second dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo in 5 mls distilled water
Study: NCT01388023

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herbal formula for fresh breath
Description: composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herbal formula for fresh breath
Description: composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herbal formula for fresh breath
Description: composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: herbal formula for fresh breath
Description: composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
Study: NCT02294071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: oral liquid ibuprofen 10mg/kg (maximum 600 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: oral liquid ibuprofen 10mg/kg (maximum 600 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: oral liquid acetaminophen 15mg/kg (max 975mg)
Study: NCT01135875

Intervention type: OTHER
Intervention: GBM Patients
Description: 2 teaspoons of blood will be collected during select clinic visits.

Intervention type: OTHER
Intervention: Normal Controls
Description: 2 teaspoons of blood will be collected once.
Study: NCT04352218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA + Stenting using Petalo stent
Description: PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
Study: NCT02157129

Intervention type: OTHER
Group type: OTHER
Intervention: Physiologic saline inhalation
Description: Physiologic saline inhalation, 5x/d for 30min
Study: NCT03557450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Description: PET/CT scanning with sodium fluoride
Study: NCT03756922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector
Study: NCT01541839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal Stapler
Description: This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.